Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma

This is a prospective, randomized, open‐label, multicenter phase II study.Newly‐diagnosed primary glioblastoma patients who have undergone maximal safe resectionor biopsy and completed standard concurrent chemoradiotherapy will be enrolled. Subjectswill be randomized 1:1 into Arm A (Adebrelimab + Temozolomide + Hyperbaric OxygenTherapy) or Arm B (Adebrelimab + Temozolomide). The primary endpoint is progression‐freesurvival(PFS). Secondary endpoints include overall survival(OS), objective responserate(ORR), disease control rate(DCR), change of KPS score, safety including TRAE, irAEand SAE. Exploratory objectives include correlation analysis between baseline clinicalcharacteristics / hyperbaric‐oxygen‐related biomarkers and efficacy‐safety outcomes.